Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...